EUVIMEDEUVIMED entdecken
Crossref

Preclinical and Initial Clinical Evaluation of 68 Ga/ 177 Lu-Labeled Heterodimer Agents Targeting Somatostatin Receptors and Integrin α V β 3

Linlin Li, Xingtong Peng, Jialin Xiang, Chenhao Jia, Rongxi Wang, Wenbin Jin, Jiarou Wang, Yanwei Wang, Yaping Luo, Yuanyuan Jiang, Zhaohui Zhu iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.5c01238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Linlin Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and …. Hauptthemen laut MEDLINE: Integrin alphaVbeta3, Receptors, Somatostatin, Gallium Radioisotopes, Radiopharmaceuticals. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Highly overexpressed somatostatin receptors (SSTRs), especially SSTR2, are frequently characterized in neuroendocrine tumors (NETs) and serve as a target for imaging and peptide receptor radionuclide therapy (PRRT). However, the SSTR2 expression decreases in higher-grade NETs, while the expression level of the integrin receptor αVβ3 was increased. A reported heterodimer, [68Ga]Ga-NOTA-3P-TATE-RGD, which targets both SSTR2 and integrin αVβ3, has shown potential clinical value, but the high renal uptake limited its further development. The aim of this study is to evaluate [68Ga]Ga/[177Lu]Lu-DOTATATE-RGD ([68Ga]Ga/[177Lu]Lu-DTR) and [68Ga]Ga-NOTA-TOC-RGD ([68Ga]Ga-NCR) as potential SSTR and integrin αvβ3 heterodimer agents. Radiolabeling of both Ga-68 and Lu-177 was effectively accomplished with high yields and radiochemical purities. The three agents showed higher cell uptake compared with monomeric [68Ga]Ga-RGD but reduced uptake compared with [68Ga]Ga-DOTATATE. Results of biodistribution and small-animal positron emission tomography (PET) studies showed that the renal uptake of [68Ga]Ga/[177Lu]Lu-DTR decreased without affecting the tumor-binding ability compared to [68Ga]Ga-NOTA-3P-TATE-RGD, but the tumor-to-kidney ratio of [68Ga]Ga-NCR did not increase as desired. In initial clinical trials, [68Ga]Ga-DTR PET/CT exhibited a lower uptake in the kidney and spleen than that of [68Ga]Ga-NOTA-3P-TATE-RGD PET/CT (SUVmean: 10.88 ± 3.27 vs 29.02 ± 8.89 and 3.41 ± 1.18 vs 8.16 ± 4.38, respectively), indicating that [68Ga]Ga/[177Lu]Lu-DTR may serve as a useful candidate ligand for theranostic agents in NET patients with a lower uptake of normal organs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Integrin alphaVbeta3Receptors, SomatostatinGallium RadioisotopesRadiopharmaceuticalsLutetiumNeuroendocrine TumorsRadioisotopesAnimalsHumansMiceTissue DistributionFemaleCell Line, TumorOctreotideMice, NudeMale

Stichwörter der Autor:innen

TATE-RGD heterodimerintegrin αVβ3neuroendocrine tumorssomatostatin receptor

Substanzen

Integrin alphaVbeta3Receptors, SomatostatinGallium RadioisotopesRadiopharmaceuticalsLutetiumRadioisotopesOctreotideLutetium-177Gallium-68

Autor:innen und Institutionen

  • Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Ch…
  • Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
  • Department of Nuclear Medicine (PET-CT Center), National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021,…

ORCID-Profile: Zhaohui Zhu

Förderung

  • National Key Research and Development Program of China
  • Chinese Academy of Medical Sciences
  • Peking Union Medical College Hospital
  • Natural Science Foundation of Beijing Municipality
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China

Zitieren

APA

Li, L., Peng, X., Xiang, J., Jia, C., Wang, R., Jin, W., Wang, J., Wang, Y., Luo, Y., Jiang, Y., & Zhu, Z. (2026). Preclinical and Initial Clinical Evaluation of 68 Ga/ 177 Lu-Labeled Heterodimer Agents Targeting Somatostatin Receptors and Integrin α V β 3. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01238

Vancouver

Li L, Peng X, Xiang J, Jia C, Wang R, Jin W, et al. Preclinical and Initial Clinical Evaluation of 68 Ga/ 177 Lu-Labeled Heterodimer Agents Targeting Somatostatin Receptors and Integrin α V β 3. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01238

BibTeX
@article{Li2026,
  author = {Li, Linlin and Peng, Xingtong and Xiang, Jialin and Jia, Chenhao and Wang, Rongxi and Jin, Wenbin and Wang, Jiarou and Wang, Yanwei and Luo, Yaping and Jiang, Yuanyuan and Zhu, Zhaohui},
  title = {Preclinical and Initial Clinical Evaluation of 68 Ga/ 177 Lu-Labeled Heterodimer Agents Targeting Somatostatin Receptors and Integrin α V β 3},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.5c01238}
}
Kostenlos starten →